CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma-Reference-Cited by-同舟云学术

CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma

Published:2018-05-09 Issue:3 Volume:245 Page:297-310
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol.

Author:

Karkampouna Sofia¹,van der Helm Danny²,Gray Peter C³,Chen Lanpeng⁴,Klima Irena¹,Grosjean Joël¹,Burgmans Mark C⁵,Farina-Sarasqueta Arantza⁶,Snaar-Jagalska Ewa B⁴,Stroka Deborah M⁷,Terracciano Luigi⁸,van Hoek Bart²,Schaapherder Alexander F⁹,Osanto Susan¹⁰,Thalmann George N¹¹¹,Verspaget Hein W²,Coenraad Minneke J²,Kruithof-de Julio Marianna¹¹¹^ORCID

Affiliation:

1. Department of Biomedical Research, Urology Group; University of Bern; Bern Switzerland

2. Department of Gastroenterology and Hepatology; Leiden University Medical Center; Leiden The Netherlands

3. Clayton Foundation Laboratories for Peptide Biology; The Salk Institute for Biological Studies; La Jolla, California USA

4. Institute of Biology, Department of Molecular Cell Biology; Leiden University; Leiden The Netherlands

5. Department of Radiology; Leiden University Medical Centre; Leiden The Netherlands

6. Department of Pathology; Leiden University Medical Centre; Leiden The Netherlands

7. Department of Biomedical Research, Visceral Surgery and Medicine; University of Bern, Bern University Hospital; Switzerland

8. Molecular Pathology Division, Institute of Pathology; University Hospital Basel; Switzerland

9. Department of Surgery; Leiden University Medical Center; Leiden The Netherlands

10. Department of Oncology; Leiden University Medical Center; Leiden The Netherlands

11. Department of Urology; Bern University Hospital; Switzerland

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Reference55 articles.

1. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study;Bray;Lancet Oncol,2012

2. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis;El-Serag;Gastroenterology,2007

3. Minimally invasive local therapies for liver cancer;Li;Cancer Biol Med,2014

4. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma;European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer;J Hepatol,2012

5. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening;Biomolecules;2024-07-04

2. CRIPTO promotes extracellular vesicle uptake and activation of cancer associated fibroblasts;2024-03-05

3. Autophagy, molecular chaperones, and unfolded protein response as promoters of tumor recurrence;Cancer and Metastasis Reviews;2023-02-01

4. LIM protein Ajuba promotes liver cell proliferation through its involvement in DNA replication and DNA damage control;FEBS Letters;2022-06-15

5. Cripto-1/Glucose-Regulated Protein 78 Affects Proliferation, Migration and Apoptosis of Ovarian Carcinoma Cells;Journal of Biomaterials and Tissue Engineering;2022-02-01